Sudhir K - Search Results

1

Pet ownership and cardiovascular risk reduction: supporting evidence, conflicting data and underlying mechanisms.

Arhant-Sudhir K, Arhant-Sudhir R, Sudhir K. Arhant-Sudhir K, et al. Among authors: sudhir k. Clin Exp Pharmacol Physiol. 2011 Nov;38(11):734-8. doi: 10.1111/j.1440-1681.2011.05583.x. Clin Exp Pharmacol Physiol. 2011. PMID: 21824172 Review.

2

Evidence for a role for the cardiovascular amplifiers in human primary hypertension.

Jennings G, Korner PI, Sudhir K, Esler M, Angus JA, Laufer E. Jennings G, et al. Among authors: sudhir k. Clin Exp Pharmacol Physiol. 1991 Jan;18(1):37-41. doi: 10.1111/j.1440-1681.1991.tb01374.x. Clin Exp Pharmacol Physiol. 1991. PMID: 2032389

3

Lipoprotein-associated phospholipase A2, vascular inflammation and cardiovascular risk prediction.

Sudhir K. Sudhir K. Vasc Health Risk Manag. 2006;2(2):153-6. doi: 10.2147/vhrm.2006.2.2.153. Vasc Health Risk Manag. 2006. PMID: 17319459 Free PMC article. Review.

4

Clinical review: Lipoprotein-associated phospholipase A2, a novel inflammatory biomarker and independent risk predictor for cardiovascular disease.

Sudhir K. Sudhir K. J Clin Endocrinol Metab. 2005 May;90(5):3100-5. doi: 10.1210/jc.2004-2027. Epub 2005 Feb 15. J Clin Endocrinol Metab. 2005. PMID: 15713711 Review.

5

Late-acquired incomplete stent apposition: morphologic characterization.

Hur SH, Ako J, Honda Y, Sudhir K, Fitzgerald PJ. Hur SH, et al. Among authors: sudhir k. Cardiovasc Revasc Med. 2009 Oct-Dec;10(4):236-46. doi: 10.1016/j.carrev.2009.02.002. Cardiovasc Revasc Med. 2009. PMID: 19815171 Review.

6

Comparison of vascular response to the everolimus-eluting stent versus the paclitaxel-eluting stent: intravascular ultrasound results from the SPIRIT III trial.

Yamasaki M, Tsujino I, Lima-Filho MO, Ako J, Shimohama T, Hasegawa T, Sakurai R, Sudhir K, Stone GW, Waseda K, Honda Y, Fitzgerald PJ. Yamasaki M, et al. Among authors: sudhir k. EuroIntervention. 2012 Oct;8(6):724-31. doi: 10.4244/EIJV8I6A112. EuroIntervention. 2012. PMID: 23086791 Free article. Clinical Trial.

7

Comparison of vascular response to zotarolimus-eluting stent vs paclitaxel-eluting stent implantation: pooled IVUS results from the ZoMaxx I and II trials.

Waseda K, Hasegawa T, Ako J, Honda Y, Grube E, Whitbourn R, Ormiston J, O'Shaughnessy CD, Henry TD, Overlie P, Schwartz LB, Sudhir K, Chevalier B, Gray WA, Yeung AC, Fitzgerald PJ; ZoMaxx I and II Trial Investigators. Waseda K, et al. Among authors: sudhir k. Circ J. 2010 Nov;74(11):2334-9. doi: 10.1253/circj.cj-09-0850. Epub 2010 Sep 28. Circ J. 2010. PMID: 20890052 Free article.

8

Comparison of vessel response following sirolimus-eluting stent implantation as assessed by serial 3-D intravascular ultrasound study.

Waseda K, Ako J, Shimada Y, Morino Y, Tsujino I, Hongo Y, Sudhir K, Yock PG, Fitzgerald PJ, Honda Y. Waseda K, et al. Among authors: sudhir k. J Invasive Cardiol. 2007 Apr;19(4):171-3. J Invasive Cardiol. 2007. PMID: 17404402

9

Enhanced contraction to noradrenaline, serotonin and nerve stimulation but normal endothelium-derived relaxing factor response in skin small arteries in human primary hypertension.

Angus JA, Jennings GL, Sudhir K. Angus JA, et al. Among authors: sudhir k. Clin Exp Pharmacol Physiol Suppl. 1992;19:39-47. doi: 10.1111/j.1440-1681.1992.tb02809.x. Clin Exp Pharmacol Physiol Suppl. 1992. PMID: 1395116

10

Altered venous responses to vasoconstrictor agonists and nerve stimulation in human primary hypertension.

Sudhir K, Angus JA, Esler MD, Jennings GL, Lambert GW, Korner PI. Sudhir K, et al. J Hypertens. 1990 Dec;8(12):1119-28. doi: 10.1097/00004872-199012000-00008. J Hypertens. 1990. PMID: 1962801

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

211 results

Search Page

Filters